Literature DB >> 23296837

Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Kang-Woo Lee1, Joo-Young Im, Jong-Min Woo, Hilary Grosso, Yoon-Seong Kim, Ana Clara Cristovao, Patricia K Sonsalla, David S Schuster, Marla M Jalbut, Jose R Fernandez, Michael Voronkov, Eunsung Junn, Steven P Braithwaite, Jeffry B Stock, M Maral Mouradian.   

Abstract

Consumption of coffee is associated with reduced risk of Parkinson's disease (PD), an effect that has largely been attributed to caffeine. However, coffee contains numerous components that may also be neuroprotective. One of these compounds is eicosanoyl-5-hydroxytryptamide (EHT), which ameliorates the phenotype of α-synuclein transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. Here, we sought to investigate if EHT has an effect in the MPTP model of PD. Mice fed a diet containing EHT for four weeks exhibited dose-dependent preservation of nigral dopaminergic neurons following MPTP challenge compared to animals given control feed. Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment. The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with EHT. In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and nitric oxide production. EHT also exhibited a robust anti-oxidant activity in vitro. Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT. These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A. Our data, therefore, reveal a strong beneficial effect of a novel component of coffee in multiple endpoints relevant to PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296837      PMCID: PMC3557367          DOI: 10.1007/s13311-012-0165-2

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  44 in total

1.  Caffeine as a protective factor in dementia and Alzheimer's disease.

Authors:  Marjo H Eskelinen; Miia Kivipelto
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies.

Authors:  João Costa; Nuno Lunet; Catarina Santos; João Santos; António Vaz-Carneiro
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model.

Authors:  Kang-Woo Lee; Walter Chen; Eunsung Junn; Joo-Young Im; Hilary Grosso; Patricia K Sonsalla; Xuyan Feng; Neelanjana Ray; Jose R Fernandez; Yang Chao; Eliezer Masliah; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neurosci       Date:  2011-05-11       Impact factor: 6.167

Review 4.  Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

Authors:  Michael Voronkov; Steven P Braithwaite; Jeffry B Stock
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

5.  Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1.

Authors:  Eun-Jung Lee; Moon-Sook Woo; Pyong-Gon Moon; Moon-Chang Baek; In-Young Choi; Won-Ki Kim; Eunsung Junn; Hee-Sun Kim
Journal:  J Immunol       Date:  2010-05-28       Impact factor: 5.422

6.  Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.

Authors:  Kien Trinh; Laurie Andrews; James Krause; Tyler Hanak; Daewoo Lee; Michael Gelb; Leo Pallanck
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

Review 7.  Neuroinflammation in Parkinson's disease: a target for neuroprotection?

Authors:  Etienne C Hirsch; Stéphane Hunot
Journal:  Lancet Neurol       Date:  2009-04       Impact factor: 44.182

8.  Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Authors:  Haiyan Lou; Susana E Montoya; Tshianda N M Alerte; Jian Wang; Jianjun Wu; Xiangmin Peng; Chang-Sook Hong; Emily E Friedrich; Samantha A Mader; Courtney J Pedersen; Brian S Marcus; Alison L McCormack; Donato A Di Monte; S Colette Daubner; Ruth G Perez
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

9.  Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells.

Authors:  Bo Su; Xinglong Wang; Hyoung-Gon Lee; Massimo Tabaton; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Neurosci Lett       Date:  2009-11-13       Impact factor: 3.046

10.  Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation.

Authors:  Kang-Woo Lee; Xin Zhao; Joo-Young Im; Hilary Grosso; Won Hee Jang; Teresa W Chan; Patricia K Sonsalla; Dwight C German; Hidenori Ichijo; Eunsung Junn; M Maral Mouradian
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

View more
  31 in total

Review 1.  Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  A J Carman; P A Dacks; R F Lane; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

2.  The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.

Authors:  Michela Campolo; Giovanna Casili; Flavia Biundo; Rosalia Crupi; Marika Cordaro; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Antioxid Redox Signal       Date:  2017-01-27       Impact factor: 8.401

Review 3.  Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.

Authors:  Md Nematullah; M N Hoda; Farah Khan
Journal:  Mol Neurobiol       Date:  2017-02-21       Impact factor: 5.590

4.  A prospective study of tea and coffee intake and risk of glioma.

Authors:  David J Cote; Alaina M Bever; Kathryn M Wilson; Timothy R Smith; Stephanie A Smith-Warner; Meir J Stampfer
Journal:  Int J Cancer       Date:  2019-07-26       Impact factor: 7.396

5.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

6.  Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.

Authors:  Gustavo Basurto-Islas; Julie Blanchard; Yunn Chyn Tung; Jose R Fernandez; Michael Voronkov; Maxwell Stock; Sherry Zhang; Jeffry B Stock; Khalid Iqbal
Journal:  Neurobiol Aging       Date:  2014-06-17       Impact factor: 4.673

7.  Chronic caffeine ingestion causes microglia activation, but not proliferation in the healthy brain.

Authors:  Rob Steger; Arifa Kamal; Sara Lutchman; Liliana Intrabartolo; Rabia Sohail; Joshua C Brumberg
Journal:  Brain Res Bull       Date:  2014-05-29       Impact factor: 4.077

8.  Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.

Authors:  Michelle Pusey; Sophie Bail; Yan Xu; Olesia Buiakova; Mariya Nestor; Jing-Jing Yang; Lyndi M Rice
Journal:  Tumour Biol       Date:  2016-04-05

9.  Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Authors:  Hye-Jin Park; Kang-Woo Lee; Stephanie Oh; Run Yan; Jie Zhang; Thomas G Beach; Charles H Adler; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

Review 10.  Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.

Authors:  Nicolas Dzamko; Jinxia Zhou; Yue Huang; Glenda M Halliday
Journal:  Front Mol Neurosci       Date:  2014-06-24       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.